Enhanced Telehealth in Prostate Cancer
Enhanced Telehealth bei Prostatakrebs
JAMA Network Open · 09.06.2026 · 9 (6) · e2617466
DOI: 10.1001/jamanetworkopen.2026.17466 ↗Auf einen Blick
In einer Qualitätsverbesserungsstudie bei Patienten mit Prostatakrebs war Enhanced Telehealth machbar. Die Patient:innen bewerteten die Komponenten und die Zufriedenheit hoch.
Fragestellung
Ist Enhanced Telehealth bei Patienten mit Prostatakrebs machbar und wie ist der Umsetzungskontext?
Methode
Multiphase-Qualitätsverbesserungsstudie an 7 ambulanten onkologischen Standorten; Phase 1 mit halbstrukturierten Interviews, Phase 2 mit Pilotprogramm; Follow-up 8 Monate.
Ergebnisse
38 Patient:innen. Completion auf Patientenebene: Telehealth 68,4 % (26/38), Blutdruckmonitoring 91,9 % (34/37), Home-Phlebotomie 96,3 % (26/27), Injektionen zu Hause 90,0 % (9/10).
Schlussfolgerung der Autor:innen
Enhanced Telehealth war machbar, mit mehr als 60 % abgeschlossenen geplanten Visiten; die Autor:innen sehen starke Unterstützung durch Patient:innen und Kliniker:innen.
Kernaussagen
- Telehealth und häusliche Leistungen waren insgesamt gut umsetzbar.
- Patient:innen bewerteten Akzeptanz, Passung und Machbarkeit hoch.
- Die Zufriedenheit war bei Patient:innen und Kliniker:innen hoch.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 09.06.2026. Verfasst von Erin M Bange und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Telemedicine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Digitalisierung in der Pflege
Abstract (Originalsprache)
Importance Prostate cancer often requires frequent in-person clinical visits, imposing substantial travel, financial, and time burdens for patients. Combining telehealth with in-home monitoring (enhanced telehealth) has the potential to make care more patient centered and efficient.
Objective
To assess the feasibility and implementation context of enhanced telehealth for patients with prostate cancer. Design, Setting, and Participants Adult patients with prostate cancer receiving androgen deprivation therapy (ADT) were enrolled in this multiphase quality improvement study of enhanced telehealth from June 1, 2023, to June 30, 2024, and followed up for 8 months. The study was conducted at 7 ambulatory oncology practice sites at Memorial Sloan Kettering, an academic comprehensive cancer center. Phase 1 included semistructured interviews with key stakeholders to assess implementation considerations of enhanced telehealth. Phase 2 piloted an enhanced telehealth program offering remote blood pressure (BP) monitoring, mobile phlebotomy, and injections at home; patients could choose to participate in any available component.
Intervention
Enhanced telehealth, a care delivery model that augments routine telehealth encounters with (1) home phlebotomy, (2) remote BP monitoring, and/or (3) at-home administration of ADT or other injectable therapies. Main Outcome and Measures The primary outcome was feasibility, assessed by completion rates for each enhanced telehealth component at the patient and visit levels. Patient and clinician satisfaction was assessed using the Net Promotor Score. Acceptability, appropriateness, and feasibility were measured using validated measures on a 5-point Likert scale.
Results
Thirty-eight patients participated; the median age was 70.0 years (IQR, 61.5-76.7 years) and 24 (63.2%) had metastatic castration-sensitive prostate cancer. Patient-level completion rates for at least 1 service were telehealth, 68.4% (26 of 38); remote BP monitoring, 91.9% (34 of 37); home phlebotomy, 96.3% (26 of 27); and at-home injections, 90.0% (9 of 10). Visit-level completion rates were high for telehealth (92.3% [60 of 65]), phlebotomy (95.4% [145 of 152]), and injections (84.6% [11 of 13]) but lower for BP monitoring (65.0% [343 of 528]). Patients rated all components as acceptable (mean [SD] score, 4.8 [0.4]; range, 3.25-5), appropriate (mean [SD] score, 4.8 [0.4]; range, 3.75-5), and feasible (mean [SD] score, 4.7 [0.5]; range, 3.25-5). Enhanced telehealth had high patient and clinician satisfaction (Net Promotor Score: patients, 82.4%; clinicians, 80.0% for telehealth, 80.6% for remote BP monitoring, 84.6% for home phlebotomy, and 75.0% for home injections). Conclusions and Relevance In this quality improvement study, enhanced telehealth was feasible, with greater than 60% completion for all scheduled visits, with strong endorsement of benefits from patients with prostate cancer as well as clinicians. These findings support further development of enhanced telehealth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- Division of Advanced Practice Providers, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Biomedical Informatics, Columbia University, New York, New York.
- Department of Medicine, Weill Cornell Medical College, New York, New York.
- Population Health, Value & Clinical Analytics, Office of the Chief Medical Officer, Memorial Sloan Kettering Cancer Center, New York, New York.
Förderung
- NCI NIH HHS
Zitieren
APA
Bange, E. M., Reiner, A. S., Liebertz, C., Malling, C., Kuperman, G., Daly, B., Chimonas, S., Marcinkowski, K., Doshi, S. D., Polubriaginof, F., Stevanovic, K., Murillo, S., Stetson, P., Schrag, D., Panageas, K. S., & Morris, M. J. (2026). Enhanced Telehealth in Prostate Cancer. JAMA Network Open, 9(6), e2617466. https://doi.org/10.1001/jamanetworkopen.2026.17466
Vancouver
Bange EM, Reiner AS, Liebertz C, Malling C, Kuperman G, Daly B, et al. Enhanced Telehealth in Prostate Cancer. JAMA Network Open. 2026;9(6):e2617466. doi:10.1001/jamanetworkopen.2026.17466
BibTeX
@article{Bange2026,
author = {Bange, Erin M and Reiner, Anne S and Liebertz, Christine and Malling, Charlotte and Kuperman, Gilad and Daly, Bobby and Chimonas, Susan and Marcinkowski, Katherine and Doshi, Sahil D and Polubriaginof, Fernanda and Stevanovic, Kristina and Murillo, Susan and Stetson, Peter and Schrag, Deborah and Panageas, Katherine S and Morris, Michael J},
title = {Enhanced Telehealth in Prostate Cancer},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {6},
pages = {e2617466},
doi = {10.1001/jamanetworkopen.2026.17466}
}
EUVIMED